Corona Remedies
Corona Remedies Share Price Chart
Corona Remedies last traded at ₹2,008.50 (2026-10-13). Over the past month the stock moved -9.1%, three months the stock moved +18.4%. Its closing range over 52 weeks is ₹1,347.70 – ₹2,236.30, with the latest close 10.2% below the high.
Closing prices up to 2026-10-13.
About Corona Remedies
Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company developing, manufacturing, and marketing products in women’s healthcare, cardiology, pain management, urology, and other therapeutic areas.[1]
Market Leadership[1] The Company holds strong positions across key therapies, ranking #5 in Women’s Healthcare, #5 in Pain Management, #9 in Urology, and #20 in Cardio-Diabeto. It is also ranked #14 in the overall Indian Pharmaceutical Market (IPM), with notable rankings of #6 in Orthopaedics, #7 in Gynaecology, #11 in Consulting Physicians and Diabetology, and #14 in Cardiology and Urology.
Fundamentals
Quarterly Results
In the latest quarter (Jun 2026), Corona Remedies reported sales of ₹422.00 crore (+21.6%) and net profit of ₹60.00 crore (+30.4%), compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 422.00 | 93.00 | 22.00 | 60.00 | 9.83 |
| Mar 2026 | 353.00 | 62.00 | 18.00 | 45.00 | 7.37 |
| Dec 2025 | 342.00 | 83.00 | 24.00 | 41.00 | 6.74 |
| Sep 2025 | 361.00 | 78.00 | 22.00 | 52.00 | 8.53 |
| Jun 2025 | 347.00 | 70.00 | 20.00 | 46.00 | 7.59 |
| Mar 2025 | 294.00 | 54.00 | 18.00 | 31.00 | 5.12 |
| Dec 2024 | 298.00 | 69.00 | 23.00 | 45.00 | 7.32 |
| Sep 2024 | 314.00 | 67.00 | 21.00 | 43.00 | 7.03 |
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Sales growth | +15.0% | +14.8% | +20.1% | +21.6% |
| Operating profit growth | +16.4% | +20.3% | +14.8% | +32.9% |
| Net profit growth | +20.9% | -8.9% | +45.2% | +30.4% |
| EPS growth | +21.3% | -7.9% | +43.9% | +29.5% |
| OPM % | 22.0% | 24.0% | 18.0% | 22.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Annual Financials
In the latest year (Mar 2026), Corona Remedies reported sales of ₹1,403.00 crore (+17.3%) and net profit of ₹185.00 crore (+24.2%), compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 1,403 | 293.00 | 21.00 | 185.00 | 30.22 |
| Mar 2025 | 1,196 | 241.00 | 20.00 | 149.00 | 24.37 |
| Mar 2024 | 1,014 | 156.00 | 15.00 | 90.00 | 14.80 |
| Mar 2023 | 884.00 | 128.00 | 14.00 | 85.00 | 13.85 |
| Mar 2022 | 617.00 | 18.00 | 3.00 | 0.00 | -0.08 |
| Mar 2021 | 576.00 | 105.00 | 18.00 | 70.00 | 150.72 |
| Mar 2020 | 601.00 | 93.00 | 15.00 | 59.00 | 126.70 |
| Mar 2019 | 509.00 | 66.00 | 13.00 | 35.00 | 74.85 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Sales growth | +18.1% | -4.2% | +7.1% | +43.3% | +14.7% | +17.9% | +17.3% |
| Operating profit growth | +40.9% | +12.9% | -82.9% | +611.1% | +21.9% | +54.5% | +21.6% |
| Net profit growth | +68.6% | +18.6% | -100.0% | – | +5.9% | +65.6% | +24.2% |
| EPS growth | +69.3% | +19.0% | -100.1% | – | +6.9% | +64.7% | +24.0% |
| OPM % | 15.0% | 18.0% | 3.0% | 14.0% | 15.0% | 20.0% | 21.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Shareholding
AI Analysis
No AI analysis generated yet for Corona Remedies.
Get Free AI Stock Analysis FREE →Latest News
-
Capital Group buys nearly 2% stake in Lotus Developers; ChrysCapital offloads over 4% stake in Corona... - Moneycontrol.com
-
ADIA, Aberdeen Group, Others Buy 7.3 PC Stake in Corona Remedies for Rs 777 Cr
-
Corona Remedies Ltd Downgraded to Sell Amid Technical and Financial Concerns
-
Corona Remedies Ltd Technical Momentum Shifts Amid Mixed Market Signals
-
CORONA Remedies rises on getting EU-GMP certification for Hormone manufacturing facility
-
CORONA Remedies gets EU-GMP certification for Hormone manufacturing facility
-
CORONA Remedies Reports Strong FY26 Performance With 17.3% Revenue Growth and 33.4% PAT Growth - scanx.trade
-
CORONA Remedies reports Profit after tax of Rs 450.50 Mln, in the March 2026 quarter
-
CORONA Remedies Reports Strong FY26 Performance With 17.3% Revenue Growth and 33.4% PAT Growth - scanx.trade
-
Corona Remedies consolidated net profit rises 43.68% in the March 2026 quarter - Business Standard
Frequently Asked Questions
What is Corona Remedies's current stock price?
Corona Remedies shares were last quoted at ₹2,008.50 (-0.8% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
What is the P/E ratio of Corona Remedies?
Corona Remedies has a price-to-earnings (P/E) ratio of 65.01 and a price-to-book (P/B) ratio of 16.03. The industry P/E is 53.33.
What is the 52-week high and low of Corona Remedies?
The 52-week high of Corona Remedies is ₹2,285.00 and the 52-week low is ₹1,336.95.
What is the market cap of Corona Remedies?
The market capitalisation of Corona Remedies is about ₹12,937.50 crore.
How did Corona Remedies perform in its latest quarterly results?
In the latest quarter (Jun 2026), Corona Remedies reported sales of ₹422.00 crore (+21.6%) and net profit of ₹60.00 crore (+30.4%), compared with the same quarter last year.
Is Corona Remedies a good stock to buy?
This page is for information and is not investment advice. As per the data shown here, Corona Remedies has a 3-year ROE of 26.00%, 3-year profit growth of 33.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
What is the promoter holding in Corona Remedies?
Promoters hold about 69.00% of Corona Remedies.